Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Crossref DOI link: https://doi.org/10.1007/s40257-017-0328-3
Published Online: 2017-10-27
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Amin, Mina
No, Daniel J.
Egeberg, Alexander
Wu, Jashin J.
License valid from 2017-10-27